Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal Phase 3 clinical trial program for NNZ-2591 to treat children with Phelan-McDermid syndrome (Telomeric-22q13-Monosomy-Syndrome)

Trial Profile

A pivotal Phase 3 clinical trial program for NNZ-2591 to treat children with Phelan-McDermid syndrome (Telomeric-22q13-Monosomy-Syndrome)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NNZ 2591 (Primary)
  • Indications Telomeric 22q13 Monosomy Syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Neuren Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2025 According to Neuren Pharmaceuticals media release, the company plans to commence the Phase 3 trial in the mid of 2025, subject to FDA review of the final version of the trial protocol.
    • 14 Apr 2025 According to Neuren Pharmaceuticals media release, primary endpoints for this trial have been confirmed at a productive Type C Meeting with the US Food and Drug Administration (FDA).
    • 25 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top